Detailed Narrative
Leadership Transition and Strategic Continuity
Alan Bash was appointed Interim CEO following Dr. Ying Huang's departure, with the Board initiating a thorough search for a permanent leader. The company emphasized that this is a leadership transition, not a strategy transition, maintaining focus on maximizing CARVYKTI, advancing the next-generation pipeline, and strengthening execution. Management reiterated commitment to continuity, transparency, and disciplined execution, leveraging a strong foundation and financial flexibility.
CARVYKTI Commercial Momentum
CARVYKTI delivered robust worldwide net trade sales of $657 million in Q2 FY26, representing 50% year-over-year growth and 10% sequential growth. U.S. sales increased 32% year-over-year and 9% quarter-over-quarter, driven by accelerating adoption in earlier lines of therapy, with 2L-4L usage now comprising over 70% of volume. Ex-U.S. sales surged 128% year-over-year and 13% quarter-over-quarter, supported by launches in 19 markets and expansion to 348 global treatment sites, including a recent launch in Ireland.
In Vivo CAR-T Platform Breakthrough
The Phase I LB2501 study, a CD19/CD20 dual-targeting in vivo CAR-T therapy for relapsed/refractory non-Hodgkin's lymphoma, presented compelling first-human data at EHA. At dose level 2, it achieved a 100% objective response rate and an 83.3% complete response rate in 6 patients, with impressive CAR T cell persistence up to 116 days. LB2501 was well tolerated with no dose-limiting toxicities, serious adverse events, or deaths. Legend plans to file a U.S. IND for LB2501 by year-end to initiate a U.S.-based clinical program.
Broader Pipeline Advancement
Legend Biotech is advancing a diversified pipeline across autologous, allogeneic, and in vivo cell therapies. Autologous programs include therapies targeting Claudin 18.2, DLL3, GPRC5D, and dual targets for multiple myeloma. Allogeneic programs are being developed for autoimmune disease and B-cell malignancies. Multiple frontline multiple myeloma studies for CARVYKTI (CARTITUDE-5, CARTITUDE-6) are ongoing, with potential to expand market opportunity into the first-line setting.
Financial Strength and Profitability
The company achieved its first quarter of company-wide profitability with adjusted net income of $63 million, reflecting operating leverage and disciplined investment. Total revenue increased 52% year-over-year, and operating margins improved to 15% from negative 9% in Q2 FY25. Legend ended the quarter with a strong cash position of $965 million, bolstered by $212 million net proceeds from a public equity offering, providing flexibility to fund pipeline programs and repay a $300 million loan to Johnson & Johnson.
CARVYKTI Positioning Against Bispecifics
Management highlighted CARVYKTI's differentiation from bispecifics, emphasizing its 'one and done' nature, potential for long-term remission, and improved outcomes when used earlier in treatment. Real-world evidence from registries suggests prolonged survival and better outcomes for patients receiving CAR-T first, supporting its optimal sequencing before other BCMA options. Legend and J&J remain aligned on CARVYKTI's potential to be a $5 billion-plus peak sales asset.
MRD as a Regulatory Endpoint
Legend Biotech is actively engaging with the FDA regarding the use of Minimal Residual Disease (MRD) as a surrogate endpoint for CAR-T therapies, particularly for the CARTITUDE-6 study. With advancing frontline therapies prolonging median PFS, MRD is seen as a necessary surrogate to accelerate the development and registration of effective therapies, allowing them to reach patients earlier in their treatment journey.